Good Day All,
One more article in the world of medical advancement. Hope it reaches
you and brings some light to your quest for good health.
God Bless You,
marty auslander
MG98 targets p16
--------------------
MGI Pharma of Bloomington, Minn., and MethylGene of Montreal have
started a phase-2 trial of MG98 for head-and-neck cancer. Patients
with recurrent or metastatic squamous-cell cancer will receive this
mRNA inhibitor that blocks methylation of the p16 gene. The companies
say they’ll initiate phase-2 trials for other cancer indications.
------------------------------------------------------------------------
This is an automatically-generated notice. If you'd like to be removed
from the mailing list, please visit the Medicine-On-Line Discussion Forum
at <http://www.meds.com/con_faq.html>, or send an email message to:
majordomo@lists.meds.com
with the subject line blank and the body of the message containing the line:
unsubscribe mol-cancer your-email-address
where the phrase your-email-address is replaced with your actual email
address.
------------------------------------------------------------------------
